Acamprosate Calcium NDC 68462-435

NDC codes

FDA NDC Directory

Product NDC (as listed)68462-435Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68462-0435Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68462-435-11	68462043511	10 BLISTER PACK in 1 CARTON (68462-435-11) / 10 TABLET, DELAYED RELEASE in 1 BLISTER PACKMarketed from Jul 16, 2013
68462-435-18	68462043518	180 TABLET, DELAYED RELEASE in 1 BOTTLE (68462-435-18)Marketed from Jul 16, 2013

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Acamprosate Calcium
Generic name (nonproprietary): acamprosate calcium
Active ingredients: Acamprosate calcium — 333 mg/1
Dosage form: Tablet, Delayed release
Route: Oral
Labeler: Glenmark Pharmaceuticals Inc., USA
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202229
Marketing start: Jul 16, 2013
Listing expires: Dec 31, 2027
Identifiers: Product ID 68462-435_6560e0ea-e882-4fcd-b523-8c5474d32f91SPL ID 6560e0ea-e882-4fcd-b523-8c5474d32f91SPL set ID 43e9ef60-2d85-4394-906b-93042fea099aRxCUI 835726UNII 59375N1D0UUPC 0368462435182

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468462043511 followed by a unit qualifier and the quantity

Package 68462-0435-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 23, 2026.

Indications (excerpt from the label)

Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence from alcohol i…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202229

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202229
Product	Strength	Form · route	Labeler	Product NDC
Acamprosate Calcium	Acamprosate calcium 333 mg/1	Tablet, Delayed releaseOral	Major Pharmaceuticals	0904-7213
Acamprosate Calcium	Acamprosate calcium 333 mg/1	Tablet, Delayed releaseOral	American Health Packaging	60687-121